CG
ANIP icon

Caprock Group’s ANI Pharmaceuticals ANIP Stock Holding History

Caprock Group’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-4,625
Closed -$269K – 445
2018
Q1 		$269K Hold
4,625
– – 0.06% 305
2017
Q4 		$334K Buy
4,625
+260
+6% +$16.2K 0.07% 267
2017
Q3 		$229K Sell
4,365
-195
-4% -$9.3K 0.05% 376
2017
Q2 		$213K Sell
4,560
-31
-0.7% -$1.5K 0.05% 368
2017
Q1 		$227K Buy
4,591
+287
+7% +$16.1K 0.05% 302
2016
Q4 		$261K Sell
4,304
-99
-2% -$6.05K 0.07% 252
2016
Q3 		$292K Buy
+4,403
New +$275K 0.07% 260

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Caprock Group's ANIP Position: Q2 2018 in Review

Caprock Group sold out of ANI Pharmaceuticals (ANIP) in Q2 2018, closing a stake of 4,625 shares — an estimated $269K sold.

Caprock Group first reported a position in ANIP in Q3 2016 and held it in 7 quarters. The position peaked at $334K in Q4 2017. 184 funds tracked by Wall St. Rank hold ANIP as of Q2 2018.

  • Caprock Group reported no remaining ANI Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Caprock Group sold 4,625 ANI Pharmaceuticals shares in Q2 2018, an estimated $269K.
  • Caprock Group first reported a position in ANI Pharmaceuticals in Q3 2016 and held it in 7 quarters.
  • Caprock Group's ANI Pharmaceuticals position peaked at $334K in Q4 2017.
  • 184 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2018.

Based on Caprock Group's 13F filing for Q2 2018, filed 23 Jul 2018.